Edesa Biotech is trading 13.04% down now at $5.00 after pricing a $25 million underwritten public offering at $5.50 per share-and-warrant combination, below the August 19 closing price of $5.75.
- Includes approximately 3.87 million shares, accompanying warrants, and pre-funded warrants, creating dilution pressure.
- Proceeds will support working capital, research, development, manufacturing, and other corporate purposes.
- The company-specific financing catalyst outweighs the stronger biotechnology sector backdrop, making the offering the clearest explanation for August 20’s decline.